Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $202.08M
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: -19.00%
• EPS Growth: -2.72%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 93,123,240
• 10 Day Avg. Volume: 1,354,975
• 30 Day Avg. Volume: 1,199,069
• PEG Ratio: -0.05
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 14.37
• P/FCF Ratio: -1.00
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -4.40
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: 0.29
• 1Y Price Target: $7.00
• Price Target Upside: 274.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $2.00 ▲(6.95% Upside)

Caribou Biosciences faces significant financial challenges, with persistent losses and cash flow issues being the most impactful factors. The technical analysis indicates bearish momentum, and the valuation metrics are unattractive due to negative earnings. The overall score reflects these substantial risks, highlighting the need for strategic improvements in financial performance and market positioning.

Positive Factors

Proprietary CRISPR Platform

Caribou's proprietary CRISPR platform is a significant competitive advantage, enabling precise genetic modifications that can drive innovation in gene editing therapies and partnerships, supporting long-term growth.

Partnerships and Collaborations

Strategic partnerships and collaborations provide Caribou with diverse revenue streams and enhance its market position by leveraging external expertise and resources, fostering sustainable growth.

Low Debt Levels

Maintaining low debt levels provides Caribou with financial flexibility and reduces risk, allowing it to focus on innovation and strategic investments without the burden of high interest obligations.

Negative Factors

Declining Revenues

Declining revenues indicate potential issues in market demand or competitive positioning, which could hinder long-term growth and profitability if not addressed through strategic initiatives.

Persistent Losses

Ongoing losses reflect operational inefficiencies or high R&D costs, which may require strategic restructuring or increased revenue generation to achieve sustainable profitability.

Negative Cash Flows

Negative cash flows can limit Caribou's ability to fund operations and invest in growth opportunities without relying on external financing, potentially impacting long-term financial health.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. is a biotechnology company focused on harnessing the power of CRISPR gene editing technology to develop innovative therapies for various diseases. The company operates primarily in the life sciences sector, offering products and services that enable researchers and developers to utilize CRISPR for gene editing applications. Caribou's core products include its proprietary CRISPR platform, which allows for precise genetic modifications, and it partners with academic institutions and pharmaceutical companies to advance cellular therapies and other biotechnological applications.

How the Company Makes Money

Caribou Biosciences generates revenue through multiple streams, including licensing agreements for its CRISPR technology, collaborations with pharmaceutical and biotechnology companies, and research grants. The company enters into partnerships that allow other firms to access its proprietary technologies for drug development, often receiving upfront payments, milestone payments based on development progress, and royalties on sales of resulting products. Additionally, Caribou may engage in grant-funded research projects that contribute to its income while furthering its technological advancements.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. While the company maintains a low level of debt, its inability to generate positive cash flows and profits poses a risk to its financial stability.

Income Statement

Caribou Biosciences has experienced declining revenue growth, with a negative growth rate in the TTM period. Gross profit margins are relatively high, indicating efficient cost management, but the company struggles with significant net losses, reflected in negative net profit margins. The EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, suggesting limited leverage and a conservative capital structure. However, the negative return on equity indicates that the company is not generating profits from its equity base. The equity ratio is moderate, showing a reasonable level of equity financing relative to total assets.

Cash Flow

Caribou Biosciences faces challenges with negative operating and free cash flows, although the free cash flow to net income ratio is slightly above 1, indicating that cash flows are somewhat aligned with net income. The company has not demonstrated positive free cash flow growth, which could impact its ability to fund operations without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.29M	9.99M	34.48M	13.85M	9.60M	12.36M
Gross Profit	-21.20M	6.07M	30.95M	10.21M	8.61M	-22.06M
EBITDA	-140.02M	-162.69M	-112.53M	-104.78M	-65.61M	-35.21M
Net Income	-157.13M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet
Total Assets	194.98M	313.31M	432.21M	373.76M	442.36M	36.05M
Cash, Cash Equivalents and Short-Term Investments	147.26M	209.54M	328.83M	247.66M	375.83M	15.95M
Total Debt	25.46M	26.49M	27.11M	27.75M	0.00	1.58M
Total Liabilities	53.14M	60.36M	63.81M	72.89M	54.53M	59.48M
Stockholders Equity	141.84M	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow
Free Cash Flow	-127.73M	-144.71M	-104.90M	-97.42M	-35.64M	-34.53M
Operating Cash Flow	-125.64M	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
Investing Cash Flow	100.20M	86.61M	-68.18M	-93.25M	-176.40M	6.36M
Financing Cash Flow	4.61M	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Negative. The current price of 1.87 is below the 20-day moving average (MA) of 2.24, below the 50-day MA of 2.24, and above the 200-day MA of 1.55, indicating a neutral trend. The MACD of -0.11 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 10.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	57 Neutral	$308.38M	―	-31.07%	―	158.54%	66.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CABA	39 Underperform	$222.37M	―	-101.06%	―	―	-17.21%
SGMO	39 Underperform	$138.30M	―	-480.02%	―	-37.13%	40.47%
CRBU	38 Underperform	$202.08M	-1.22	-74.28%	―	-19.00%	-2.72%
VOR	33 Underperform	$204.51M	―	―	―	―	-1072.48%
ELTX	30 Underperform	$149.50M	-2.19	―	―	―	17.36%

Caribou Biosciences Corporate Events

Caribou Biosciences Reports Increased Losses Amid R&D Focus

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in CRISPR genome-editing technologies to develop transformative therapies, particularly focusing on allogeneic CAR-T cell therapies for hematologic malignancies. In its latest earnings report, Caribou Biosciences revealed a net loss of $121.6 million for the nine months ending September 30, 2025, compared to a net loss of $113.6 million in the same period in 2024. The company’s revenue from licensing and collaboration slightly decreased to $7.2 million from $7.9 million year-over-year. Despite the financial losses, the company continues to invest heavily in research and development, with expenses totaling $85.6 million for the nine months ended September 30, 2025. Caribou Biosciences also reported a significant impairment charge of $12.2 million, primarily due to the full impairment of its investment in Edge Animal Health. Looking forward, Caribou Biosciences’ management remains focused on advancing its product candidates through clinical development and securing additional capital to support its operations, with existing cash and marketable securities expected to fund operations for at least the next 12 months.

Caribou Biosciences Reports Positive ANTLER Phase 1 Results

On November 3, 2025, Caribou Biosciences announced positive results from its ANTLER phase 1 trial, demonstrating that its allogeneic CAR-T cell therapy, vispacabtagene regedleucel (vispa-cel), shows efficacy and durability comparable to autologous CAR-T therapies in treating relapsed or refractory B cell non-Hodgkin lymphoma. The trial results highlight vispa-cel’s potential as a best-in-class therapy due to its off-the-shelf availability and favorable safety profile, which allows for outpatient administration. Additionally, the company shared data from its CaMMouflage phase 1 trial for CB-011, targeting multiple myeloma, and announced plans for a phase 3 trial for vispa-cel in large B cell lymphoma patients ineligible for transplant.

The most recent analyst rating on (CRBU) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.

Caribou Biosciences’ CRISPR-Edited CAR-T Therapy: A Promising Step in Multiple Myeloma Treatment

Study Overview: Caribou Biosciences, Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma’ (CaMMouflage Trial). The study aims to evaluate the safety, optimal dosing, and efficacy of CB-011 in treating relapsed or refractory multiple myeloma, a condition where the disease returns or does not respond to existing treatments.

Caribou Biosciences’ Long-Term Study: A Key Update for Investors

Caribou Biosciences, Inc. is conducting a long-term follow-up study titled ‘An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy.’ The study aims to evaluate the long-term safety of investigational Caribou therapies in patients who participated in previous Caribou-sponsored clinical studies or special access programs. This research is significant as it seeks to ensure the safety and efficacy of treatments over a 15-year period post-infusion, focusing on conditions like Non-Hodgkin Lymphoma and other hematologic malignancies.

Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study

Caribou Biosciences, Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)’. The study aims to evaluate the safety, emerging efficacy, pharmacokinetics, and immunogenicity of CB-010 in adults with relapsed or refractory B cell non-Hodgkin lymphoma. This study is significant as it explores innovative gene-editing technology to potentially offer new treatment options for patients with limited alternatives.